PDF) Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice
BVT Technologies | Strazek
KONGRES MAGAZINE SPRING ISSUE by KONGRES MAGAZINE - Issuu